First it was GE Healthcare. Then it was Nanogen. And later still it was Applied Biosystems. The playing field certainly got smaller last year as several manufacturers gave up on marketing arrays for use in both research and diagnostics, despite that fact that vendors such as Affymetrix and Illumina reported increasing array revenues driven by new chips.
From the perspective of long-term consumers of microarray technology, the exit of several array vendors from the marketplace was a predictable consequence and indicative of any new technology market as it matures.